Phase 2 randomized, double-blind, placebo-controlled clinical trial of T3D-959 in mild to moderate alzheimer's disease subjects
Ended Project Grant Awarded Last action
- Award ID
- R01AG061122
- Recipient
-
T3D Therapeutics, Inc. UEI NNGUW8XDL245
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $43,992,007
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Funding
-
- $38,465,468.00 Federal
- $5,526,539.00 Non-federal
- Place of performance
- Research Triangle Park, Durham, NC, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,520,269 | $0 | |
| Amendment | $1,520,269 | $0 | |
| Amendment | $5,526,538 | $0 | |
| Amendment | $5,526,538 | $0 | |
| Amendment | $5,526,538 | $0 | |
| Amendment | $5,526,539 | $0 | |
| Amendment | $5,526,539 | $5,526,539 | |
| Amendment | $2,396,962 | $0 | |
| Amendment | $3,102,477 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $2,292,799 | $0 |
Show all 14
Quick answers
Who received award R01AG061122?
R01AG061122 was awarded to T3D Therapeutics, Inc. by National Institute on Aging (National Institutes of Health) on May 1, 2019.
How much is award R01AG061122 worth?
$43,992,007 has been obligated on R01AG061122: $38,465,468 in federal funding and $5,526,539 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award